Study guide

4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers

Nutritionist-Dietitian Licensure Examination NDLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Licensure Law, Ethics, and the Clinical Nutritionist-Dietitian

1.1 NDLE Format, Scoring Rules, and RA 10862 Licensure Requirements 1.2 Scope of Practice, Professional Ethics, and Discipline under RA 10862 1.3 Role of the Clinical Nutritionist-Dietitian, Diet Orders, and Standard Hospital Diets

2 Chapter 2: Anatomy and Physiology for Nutrition I

2.1 Cells, Tissues, Membranes, and the Immune and Lymphatic Systems 2.2 The Digestive System: Organs, Enzymes, GI Hormones, and the Liver 2.3 Endocrine and Nervous System Regulation of Metabolism and Appetite

3 Chapter 3: Anatomy and Physiology II, Energy, and Carbohydrate Metabolism

3.1 Cardiovascular, Respiratory, Renal, Musculoskeletal, and Reproductive Systems 3.2 Energy Metabolism and Energy Expenditure Calculations 3.3 Carbohydrate Chemistry, Digestion, and Glycemic Pathways

4 Chapter 4: Protein, Lipid, Mineral, and Fluid Biochemistry

4.1 Protein Chemistry, Amino Acid Metabolism, and Nitrogen Balance 4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers 4.3 Minerals, Water, Electrolytes, and Acid-Base Balance

5 Chapter 5: Basic Nutrition: Vitamins, Minerals, and the PDRI

5.1 Vitamin Biochemistry: Coenzyme Functions and Deficiency Syndromes 5.2 Vitamins and Minerals: PDRI Values, Food Sources, Bioavailability, Stability, and Toxicity 5.3 Philippine Dietary Reference Intakes (PDRI 2015), Pinggang Pinoy, and Dietary Guidelines

6 Chapter 6: Diet Computation and Clinical Nutrition Assessment

6.1 Food Exchange Lists, Meal Plan Computation, Food Labels, and Nutrient Density 6.2 Computing Desirable Body Weight, Total Energy Requirement, and the Diet Prescription 6.3 ABCD Methods of Clinical Nutrition Assessment

7 Chapter 7: Nutrition Diagnosis, Life-Stage Assessment, and Laboratory Data

7.1 Nutrition Diagnosis, PES Statements, and Medical Record Documentation 7.2 Pediatric, Obstetric, and Geriatric Clinical Nutritional Assessment 7.3 Interpreting Biochemical and Laboratory Data in Nutrition Assessment

8 Chapter 8: Drug-Nutrient Interactions, Diabetes, and Weight Disorders

8.1 Drug-Nutrient Interactions and Nutrient Depletion 8.2 MNT for Diabetes Mellitus and Endocrine Disorders 8.3 MNT for Overweight, Obesity, and Underweight

9 Chapter 9: MNT for Cardiovascular, Renal, and Gastrointestinal Disease

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia 9.2 MNT for Renal Diseases (AKI, CKD Stages 1-5, Dialysis, and Nephrotic Syndrome) 9.3 MNT for Disorders of the Gastrointestinal Tract

10 Chapter 10: MNT for Liver, Infectious, Respiratory, Allergic, and Neurologic Conditions

10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders 10.2 MNT for Fevers, Infections, Diarrheal Disease, and Respiratory Disorders 10.3 MNT for Food Allergy and Intolerance, Skin, Rheumatic, Musculoskeletal, and Neurologic Disorders

11 Chapter 11: Critical Illness, Oncology, HIV, and Protein-Energy Malnutrition

11.1 MNT in Critical Illness, Sepsis, Trauma, and Burns 11.2 MNT in Oncology: Cancer Cachexia and Treatment Side Effects 11.3 MNT for HIV/AIDS and for Protein-Energy Malnutrition in Children and Adults

12 Chapter 12: Metabolic Disorders, Dysphagia, and Enteral Nutrition

12.1 MNT for Inborn Errors of Metabolism and Eating Disorders 12.2 Dysphagia, IDDSI Texture-Modified Diets, and Adaptive Feeding 12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

13 Chapter 13: Parenteral Nutrition, Refeeding, and Nutrition Counseling

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding 13.2 Refeeding Syndrome and Complications of Parenteral Nutrition 13.3 Nutrition Counseling and Behavior Change Theories

14 Chapter 14: Nutrition Updates: Supplements, Diet Trends, and Sports Nutrition

14.1 Dietary Supplements, Herbal Medicines, and Functional Foods 14.2 Vegetarian Diets, Protein Complementation, and Popular Diet Trends 14.3 Sports Nutrition and Workplace Wellness Programs

15 Chapter 15: Community Nutrition and Population Assessment

15.1 Community Nutrition Principles, the ND's Roles, and the Philippine Health Delivery System 15.2 Nutritional Epidemiology and Health Status Indicators in the Philippines 15.3 Assessment of Community Nutritional Status and Operation Timbang Plus (OPT+)

16 Chapter 16: Dietary Surveys, Nutrition Research, and Surveillance

16.1 Food Consumption Surveys, Biochemical Tests in Surveys, and Clinical Signs of Deficiency 16.2 Food and Nutrition Research Methods, Sampling, Sample Size, and Research Ethics 16.3 National Nutrition Surveys, Demographic Data, and Designing a Nutrition Surveillance System

17 Chapter 17: Nutrition Education and Program Evaluation

17.1 Nutrition Education: Definition, Principles of Learning, Methods, and Teaching Aids 17.2 Designing a Nutrition Education Program and Measuring Customer Satisfaction 17.3 Program Planning Cycle, SMART Objectives, and Types of Evaluation

18 Chapter 18: Program Planning, Interventions, and Food Security

18.1 Nutrition Program Planning: Needs, Priorities, Constraints, Goals, and Using Evaluation Results 18.2 Nutrition Interventions and Programs for Specific Population Groups 18.3 Food and Nutrition Security, Dietary Diversity, and Vulnerable Populations

19 Chapter 19: Nutrition Governance, Networking, and Program History

19.1 National Nutrition Council (NNC) Structure and Philippine Plan of Action for Nutrition (PPAN) 19.2 Nutrition Agencies, Networking, Community Linkages, Teamwork, and Nutrition Legislation 19.3 Development of Philippine Nutrition Programs and the Country's Nutrition Problems

20 Chapter 20: Fortification, Feeding, and First 1,000 Days Laws

20.1 Food Fortification (RA 8976), Salt Iodization (RA 8172), and the 2024 Salt Industry Law 20.2 Supplementary Feeding Programs (RA 11037) and DSWD/DepEd Interventions 20.3 First 1,000 Days Law (RA 11148) and Maternal-Child Interventions

21 Chapter 21: Nutrition in the Life Cycle I

21.1 Infant and Young Child Feeding (IYCF), Philippine Milk Code (EO 51), and RA 10028 21.2 Nutrition in Pregnancy and Lactation: Physiology, Needs, Meal Patterns, and Problems 21.3 Nutrition from Infancy to School Age: Growth, Feeding Patterns, Problems, and School Programs

22 Chapter 22: Nutrition in the Life Cycle II

22.1 Nutrition for Adolescents and Adults: Growth Spurt, Risk Factors, and NCD Prevention 22.2 Nutrition for Older Adults: Aging Changes, Needs, Problems, and Senior Citizen Programs

23 Chapter 23: Food Science and Plant Foods

23.1 Chemistry of Starches, Proteins, Lipids, and Emulsions in Cooking 23.2 Food Pigments, Flavor Chemistry, and Browning Reactions (Maillard & Enzymatic) 23.3 Fruits, Vegetables, and Legumes: Classification, Market Forms, Quality, Storage, and Cookery

24 Chapter 24: Animal Foods, Cereals and Baking, and Cooking Methods

24.1 Meat, Poultry, Fish, Eggs, and Milk: Structure, Quality, Storage, and Cookery 24.2 Cereals, Flour Mixtures and Baking, Sugar Cookery, Fats and Oils, and Beverages 24.3 Heat Transfer, Dry-Heat and Moist-Heat Cooking Methods, and Filipino Cooking Techniques

25 Chapter 25: Culinary Skills, Family Meal Planning, and Food Quality

25.1 Culinary Vocabulary, Knife Cuts, Basic Sauces, and Accurate Measurement 25.2 Meal Planning for the Family, Food Budgeting, and Recipe Development 25.3 Sensory Evaluation, Objective Food Tests, and Quality Assurance in Food Production

26 Chapter 26: Food Microbiology, Preservation, and Food Law

26.1 Foodborne Pathogens, Microbial Kinetics, and FAT TOM Parameters 26.2 Food Preservation Methods, Thermal Processing, and Packaging 26.3 Philippine Food Laws, Regulatory Agencies, and Food Labeling

27 Chapter 27: Sanitation, HACCP, Waste, and Workplace Safety

27.1 Sanitation Standard Operating Procedures (SSOP) and Good Manufacturing Practices (GMP) 27.2 HACCP Principles and Critical Control Point Management in Food Service 27.3 Waste Management, Pest Control Regulation, and Occupational Safety in Food Service

28 Chapter 28: Food Service Systems, Production Planning, and Menus

28.1 Types of Food Service Delivery Systems (Conventional, Ready-Prepared, Commissary, Assembly) 28.2 Forecasting, Production Planning, and Quantity Food Production Techniques 28.3 Institutional Menu Planning, Modified Diets, and Recipe Standardization

29 Chapter 29: Distribution, Purchasing, and Storage

29.1 Food Distribution and Service Systems in Hospitals and Other Institutions 29.2 Food Purchasing Methods, Specifications, and Receiving 29.3 Storage Management, Inventory Control, and Valuation

30 Chapter 30: Cost Control, Financial Management, and Facility Layout

30.1 Food Cost Accounting, Yield Testing, and Portion Control Formulas 30.2 Menu Pricing Models, Break-Even Analysis, and Financial Statements 30.3 Food Service Facility Layout, Equipment Selection, and Workflow Ergonomics

31 Chapter 31: Equipment, Management, and Human Resources

31.1 Food Service Equipment: Selection, Capacity, Life-Cycle Cost, Depreciation, and Maintenance 31.2 Management Functions, Theories, Leadership Styles, and Managing Change in Food Service 31.3 Human Resource Management: Job Design, Recruitment, Training, Appraisal, and Discipline

32 Chapter 32: Labor Law, Permits, and Food Service Marketing

32.1 Philippine Labor Laws and Business Permits for Food Service Operations 32.2 Food Service Marketing, Menu Engineering, and Sustainable Food Service

4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers

Key Takeaways Explain This Topic AI

Saturated fatty acids with 12 to 16 carbon chains (lauric, myristic, palmitic) exert the most pronounced LDL-elevating atherogenic effects, whereas long-chain omega-3 PUFAs (EPA, DHA) reduce hepatic triglyceride synthesis and generate anti-inflammatory eicosanoids.

Apolipoprotein C-II functions as an obligate allosteric cofactor for capillary endothelial lipoprotein lipase (LPL), enabling the hydrolysis of core triglycerides from circulating chylomicrons and VLDL.

Mitochondrial β \beta β -oxidation of long-chain fatty acids requires the carnitine shuttle, with Carnitine Palmitoyltransferase-1 (CPT-1) serving as the rate-limiting enzyme that is allosterically inhibited by cytosolic malonyl-CoA.

Ketogenesis occurs exclusively in liver mitochondria when excess acetyl-CoA overwhelms the citric acid cycle during prolonged fasting or insulin deficiency, producing acetoacetate and β \beta β -hydroxybutyrate that serve as vital fuels for extrahepatic tissues.

The Friedewald formula calculates LDL cholesterol ( LDL-C = TC − HDL-C − TG 5 \text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5} LDL-C = TC − HDL-C − 5 TG ​ ) in mg/dL, but becomes inaccurate when fasting serum triglycerides reach or exceed 400 mg/dL 400\text{ mg/dL} 400 mg/dL ( 4.5 mmol/L 4.5\text{ mmol/L} 4.5 mmol/L ), requiring direct LDL measurement or non-HDL cholesterol monitoring.

Last updated: October 2026

Lipids are water-insoluble, hydrophobic or amphipathic organic macromolecules soluble in non-polar organic solvents. Dietary lipids furnish approximately 9 kcal/g (37.7 kJ/g) of energy, provide structural building blocks for cell membranes, facilitate the absorption of fat-soluble vitamins, and supply precursors for bioactive lipid mediators (eicosanoids, docosanoids, and steroid hormones). In clinical practice and public health nutrition, balancing lipid subtypes is fundamental to preventing atherosclerotic cardiovascular disease (ASCVD), managing non-alcoholic fatty liver disease (NAFLD/MASLD), and treating acute pancreatitis secondary to severe hypertriglyceridemia.

Lipid Chemistry and Fatty Acid Classification

Fatty acids consist of a terminal carboxyl group ( − C O O H -COOH − COO H , carbon 1) linked to an aliphatic hydrocarbon chain of variable length. Systematic nomenclature designates carbon chain length and the position of double bonds relative to the carboxyl carbon ( Δ \Delta Δ system) or terminal methyl carbon ( ω \omega ω or n- system).

1. Saturated Fatty Acids (SFAs)

SFAs contain no double bonds along the carbon chain, allowing tight intermolecular packing and high melting points (solid at ambient temperature):

Lauric Acid ( C 12 : 0 C12:0 C 12 : 0 ): Coconut oil, palm kernel oil.

Myristic Acid ( C 14 : 0 C14:0 C 14 : 0 ): Nutmeg butter, whole dairy fat, coconut oil.

Palmitic Acid ( C 16 : 0 C16:0 C 16 : 0 ): Palm oil, animal fats. The most abundant dietary SFA.

Stearic Acid ( C 18 : 0 C18:0 C 18 : 0 ): Cocoa butter, beef tallow.

Atherogenic Potential: Lauric, myristic, and palmitic acids downregulate hepatic LDL receptor expression, decreasing LDL clearance and significantly raising plasma LDL-C . In contrast, stearic acid ( C 18 : 0 C18:0 C 18 : 0 ) exerts a neutral effect on serum LDL-C because it is rapidly converted in hepatocytes into oleic acid ( C 18 : 1 , n − 9 C18:1, n-9 C 18 : 1 , n − 9 ) by the microsomal enzyme stearoyl-CoA desaturase ( Δ 9 \Delta^9 Δ 9 -desaturase).

2. Monounsaturated Fatty Acids (MUFAs)

MUFAs contain a single double bond, almost universally in the cis geometric configuration in nature, introducing a 30-degree rigid bend into the acyl chain:

Oleic Acid ( 18 : 1 , n − 9 18:1, n-9 18 : 1 , n − 9 or 18 : 1 Δ 9 18:1\Delta^9 18 : 1 Δ 9 ): The predominant dietary MUFA, abundant in olive oil, canola oil, avocados, and nuts. When substituted for dietary SFAs, oleic acid lowers LDL-C while preserving anti-atherogenic HDL-C concentrations and improving insulin sensitivity.

3. Polyunsaturated Fatty Acids (PUFAs)

PUFAs contain two or more cis double bonds separated by a single methylene carbon ( − C H 2 − -CH_2- − C H 2 ​ − bridge):

Omega-3 ( n − 3 n-3 n − 3 ) Fatty Acids:

α \alpha α -Linolenic Acid (ALA, 18 : 3 , n − 3 18:3, n-3 18 : 3 , n − 3 ): Indispensable dietary fatty acid found in flaxseed, chia seeds, walnuts, and canola oil.

Eicosapentaenoic Acid (EPA, 20 : 5 , n − 3 20:5, n-3 20 : 5 , n − 3 ) and Docosahexaenoic Acid (DHA, 22 : 6 , n − 3 22:6, n-3 22 : 6 , n − 3 ): Long-chain marine omega-3 fatty acids synthesized poorly in humans from ALA ( < 5 % < 5\% < 5% conversion efficiency for EPA, < 0.5 % < 0.5\% < 0.5% for DHA) due to low Δ 6 \Delta^6 Δ 6 -desaturase activity. EPA and DHA incorporate into cell membranes, displacement of arachidonic acid, and serve as substrates for anti-inflammatory, anti-thrombotic series-3 prostaglandins ( P G E 3 PGE_3 PG E 3 ​ ) , series-5 leukotrienes ( L T B 5 LTB_5 L T B 5 ​ ) , and specialized pro-resolving mediators (SPMs: resolvins, protectins, maresins) . High-dose EPA/DHA (2–4 g/day) reduces hepatic VLDL secretion and lowers plasma triglycerides by 20–30%.

Omega-6 ( n − 6 n-6 n − 6 ) Fatty Acids:

Linoleic Acid (LA, 18 : 2 , n − 6 18:2, n-6 18 : 2 , n − 6 ): Indispensable dietary fatty acid found in soybean, corn, and sunflower oils.

Arachidonic Acid (AA, 20 : 4 , n − 6 20:4, n-6 20 : 4 , n − 6 ): Abundant in meat, poultry, and egg yolks. Cleaved from membrane phospholipids by phospholipase A2 ( P L A 2 PLA_2 P L A 2 ​ ), AA enters the cyclooxygenase (COX-1/COX-2) and 5-lipoxygenase (5-LOX) pathways, producing pro-inflammatory, pro-thrombotic series-2 prostaglandins ( P G E 2 PGE_2 PG E 2 ​ ) , thromboxane A 2 A_2 A 2 ​ ( T X A 2 TXA_2 TX A 2 ​ ) , and series-4 leukotrienes ( L T B 4 LTB_4 L T B 4 ​ ) .

4. Trans Fatty Acids (TFAs)

Trans fatty acids contain double bonds in the trans geometric configuration (hydrogen atoms on opposite sides of the carbon-carbon double bond), causing the acyl chain to adopt a straight, rigid conformation resembling an SFA:

Sources: Industrial partial hydrogenation of vegetable oils (historically used in shortening, margarines, and commercial baked goods) and ruminant biohydrogenation (vaccenic acid in dairy and beef fat).

Metabolic Harm: Industrial TFAs markedly increase atherogenic LDL-C , decrease protective HDL-C , increase plasma triglycerides, elevate lipoprotein(a) [Lp(a)], and trigger systemic endothelial inflammation.

Philippine Regulatory Framework: Following the WHO REPLACE package, the Department of Health issued Administrative Order No. 2021-0039 (June 18, 2021), the national policy on eliminating industrially produced trans fat. It prohibits partially hydrogenated oils (PHOs), oils and fats blended with PHOs, oils and fats with more than 2 g of trans fat per 100 g, and processed foods made with PHOs or high in trans fat, with the goal of keeping trans fat intake below 1% of energy.

5. Triglycerides, Phospholipids, and Sterols

Triglycerides (Triacylglycerols, TAGs): Composed of a glycerol molecule esterified with three fatty acid chains. Represents 95% of dietary lipids and the primary dense metabolic energy reserve in adipose droplets.

Phospholipids: Amphipathic lipids featuring a glycerol backbone esterified to two fatty acids at sn-1 and sn-2, and a polar phosphate headgroup at sn-3 linked to an amino alcohol (choline → \to → phosphatidylcholine / lecithin ; ethanolamine → \to → phosphatidylethanolamine). Form the structural lipid bilayer of cellular membranes and the outer monolayer of plasma lipoproteins.

Sterols: Characterized by a four-ring cyclopentanoperhydrophenanthrene cyclopentane core. Cholesterol is the principal animal sterol, serving as a structural membrane fluidity modulator and metabolic precursor for bile acids, steroid hormones, and 7-dehydrocholesterol. Plant sterols and stanols ( phytosterols ) possess modified side chains that competitively displace cholesterol from mixed micelles in the intestinal lumen, reducing dietary cholesterol absorption by 30–50% without being absorbed themselves.

  • Lipid Digestion, Micelle Formation, and Absorption Dietary Lipids (TAGs, Phospholipids, Cholesteryl Esters)
  • │
  • ▼ [Mouth: Lingual Lipase]
  • Short- and Medium-Chain Fatty Acid Cleavage initiated
  • │
  • ▼ [Stomach: Gastric Lipase + Mechanical Shearing]
  • 10–30% of TAGs cleaved to 1,2-DAGs + FFAs (Emulsion Droplets)
  • │
  • ▼ [Duodenum: CCK stimulates Gallbladder & Pancreas]
  • Bile Salts Emulsify Lipids ──► Mixed Droplets
  • │
  • ▼ [Pancreatic Colipase anchors Pancreatic Lipase at droplet interface]
  • Pancreatic Lipase Cleaves sn-1 & sn-3 bonds
  • │
  • ▼
  • Products: 2-Monoacylglycerol (2-MAG) + 2 Free Fatty Acids
  • │
  • ▼ [Mixed Micelle Assembly (Bile Salts + 2-MAG + FFAs + Fat-Soluble Vitamins)]
  • Diffusion across Unstirred Water Layer to Enterocyte Brush Border
  • │
  • ├──────────────────────────────┬──────────────────────────────┐
  • ▼ ▼ ▼
  • Long-Chain FFAs & 2-MAG Short- & Medium-Chain FAs Free Cholesterol
  • (Passive & CD36/FATP4) (C6–C12: Direct Diffusion) (NPC1L1 Transporter)
  • │ │ │
  • ▼ [ER Re-esterification] ▼ [Enters Portal Blood] ▼ [ACAT2 Re-esterification]
  • Resynthesized TAGs Directly to Liver via Albumin Cholesteryl Esters
  • │ │
  • └──────────────────────────────┬──────────────────────────────┘
  • │
  • ▼ [Microsomal Triglyceride Transfer Protein (MTP)]
  • Nascent Chylomicrons (Apo B-48)
  • │
  • ▼ [Exocytosis into Lacteals]
  • Thoracic Duct ──► Systemic Blood
  • Luminal Enzymatic Hydrolysis

Lingual and Gastric Lipases: Secreted by Ebner's glands of the tongue and gastric chief cells. Acid-stable enzymes (optimum pH 4.0–5.5) that preferentially hydrolyze ester bonds at the sn-3 position of triglycerides containing short- and medium-chain fatty acids. Crucial in neonates, digesting up to 50% of dietary milk fat before pancreatic function matures.

Bile Salts and Duodenal Emulsification: Mechanical antral contractions pump coarse lipid droplets into the duodenum. Cholecystokinin (CCK) stimulates gallbladder contraction, releasing amphipathic bile salts (glycocholate, taurocholate). Bile salts reduce interfacial tension, dispersing large lipid droplets into fine microscopic emulsion particles.

Pancreatic Lipase and Colipase: Pancreatic lipase is normally inhibited and displaced from lipid droplets by bile salts. Pancreatic acinar cells co-secrete procolipase , which is cleaved by luminal trypsin into colipase . Colipase anchors pancreatic lipase to the oil-water interface, enabling it to cleave the sn-1 and sn-3 ester bonds of TAGs, yielding 2-monoacylglycerol (2-MAG) and two free fatty acids (FFAs) .

Cholesterol Esterase and Phospholipase A2: Pancreatic cholesterol esterase hydrolyzes cholesteryl esters into free cholesterol and fatty acids. Phospholipase A2 cleaves the sn-2 fatty acid of lecithin, yielding lysophosphatidylcholine .

Mixed Micelles and Enterocyte Uptake

When bile salt concentrations exceed the critical micellar concentration (CMC) (typically 2–5 mM), bile salts aggregate with 2-MAG, FFAs, free cholesterol, and fat-soluble vitamins to form cylindrical mixed micelles (4–8 nm diameter). Mixed micelles diffuse across the acidic, unstirred water layer to the brush border:

Monosaccharide/Lipid Absorption: Fatty acids and 2-MAG passively partition into the enterocyte apical membrane or are transported via fatty acid translocase ( FAT / CD36 ) and fatty acid transport proteins ( FATP4 ).

Niemann-Pick C1-Like 1 (NPC1L1): A dedicated apical sterol transporter mediating the active uptake of free cholesterol into the enterocyte. Targeted clinically by the lipid-lowering drug ezetimibe , which selectively blocks NPC1L1 to reduce intestinal cholesterol absorption.

Medium-Chain Triglycerides (MCTs): Unique Clinical Transport

Medium-chain fatty acids ( C 6 : 0 C6:0 C 6 : 0 to C 12 : 0 C12:0 C 12 : 0 , found in MCT oil and coconut oil) bypass traditional lipid digestion:

Hydrolyzed rapidly and completely by gastric and pancreatic lipases without requiring bile salt micellar incorporation.

Absorbed directly into enterocytes and pass directly across the basolateral membrane into the portal venous blood , binding to circulating serum albumin and traveling straight to the liver.

Do not require enterocyte chylomicron assembly, lymphatic lacteal drainage, or the carnitine shuttle for mitochondrial entry. Consequently, MCT oil is an indispensable medical nutrition therapy for patients with pancreatic exocrine insufficiency, biliary atresia, short bowel syndrome, chylothorax, and intestinal lymphangiectasia .

Lipoprotein Metabolism and Apolipoprotein Functions

Lipoproteins are spherical macromolecular complexes composed of a hydrophobic core (triglycerides and cholesteryl esters) surrounded by an amphipathic monolayer of phospholipids, unesterified cholesterol, and specific surface proteins called apolipoproteins .

Lipoprotein Class Density (g/mL) Major Core Lipid Characteristic Apolipoproteins Metabolic Function & Clinical Role

Chylomicrons < 0.95 < 0.95 < 0.95 Dietary TAGs (85–90%) Apo B-48 , Apo A-1, Apo C-II, Apo E Transport dietary lipids from enterocyte lacteals to peripheral tissues

VLDL 0.95 – 1.006 0.95–1.006 0.95–1.006 Endogenous TAGs (55–65%) Apo B-100 , Apo C-II, Apo E Synthesized in liver; delivers endogenous triglycerides to adipose and muscle

IDL 1.006 – 1.019 1.006–1.019 1.006–1.019 Cholesteryl Esters & TAGs Apo B-100 , Apo E VLDL remnant formed after LPL action; precursor to LDL or cleared by liver

LDL 1.019 – 1.063 1.019–1.063 1.019–1.063 Cholesteryl Esters (~50%) Apo B-100 Delivers cholesterol to peripheral cells; primary atherogenic lipoprotein

HDL 1.063 – 1.210 1.063–1.210 1.063–1.210 Protein (40–55%) & Phospholipids Apo A-1 , Apo A-2, Apo C-II, Apo E Mediates Reverse Cholesterol Transport (RCT) from tissues to liver; anti-atherogenic

Apolipoprotein Functions

Apolipoprotein B-48 (Apo B-48): Synthesized exclusively in enterocytes via post-transcriptional RNA editing of the Apo B mRNA (cytidine deaminase edits a CAA codon to a premature UAA stop codon). Apo B-48 lacks the LDL receptor-binding domain and serves as the obligatory structural scaffold for chylomicron assembly via microsomal triglyceride transfer protein (MTP).

Apolipoprotein B-100 (Apo B-100): Synthesized in hepatocytes as the full-length protein. Serves as the structural protein of VLDL, IDL, and LDL. Contains the specific ligand domain recognized by the hepatic and peripheral LDL Receptor (LDLR) .

Apolipoprotein C-II (Apo C-II): Transferred from circulating HDL to nascent chylomicrons and VLDL. Functions as the obligatory allosteric cofactor and activator of Lipoprotein Lipase (LPL) anchored to capillary endothelial surfaces in skeletal muscle, myocardium, and adipose tissue. Congenital Apo C-II deficiency causes Familial Chylomicronemia Syndrome (Type I Hyperlipoproteinemia) , characterized by massive hypertriglyceridemia ( > 1,000 – 2,000 mg/dL > 1{,}000–2{,}000\text{ mg/dL} > 1 , 000–2 , 000 mg/dL ), eruptive xanthomas, lipemia retinalis, and recurrent, life-threatening acute pancreatitis.

Apolipoprotein E (Apo E): Serves as a high-affinity ligand mediating receptor-mediated endocytosis of chylomicron remnants and IDL by hepatic LDL receptors and LDL receptor-related protein 1 (LRP1). Polymorphisms in the APOE gene ( ϵ 2 , ϵ 3 , ϵ 4 \epsilon2, \epsilon3, \epsilon4 ϵ 2 , ϵ 3 , ϵ 4 ) influence cardiovascular and neurological risk: A P O E ϵ 4 APOE\,\epsilon4 A POE ϵ 4 significantly elevates the risk of late-onset Alzheimer's disease and premature atherosclerosis; A P O E ϵ 2 / ϵ 2 APOE\,\epsilon2/\epsilon2 A POE ϵ 2/ ϵ 2 homozygosity causes Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia) .

Apolipoprotein A-1 (Apo A-1): The major structural apolipoprotein of HDL. Activates Lecithin-Cholesterol Acyltransferase (LCAT) , the plasma enzyme that esterifies free cholesterol with a fatty acid from phosphatidylcholine, trapping cholesteryl esters inside the HDL core and driving the maturation of nascent discoidal HDL into spherical mature H D L 3 HDL_3 HD L 3 ​ and H D L 2 HDL_2 HD L 2 ​ .

  • Central Pathways of Lipid Metabolism
  • 1. Mitochondrial β \beta β -Oxidation and the Carnitine Shuttle

β \beta β -Oxidation is the cyclic catabolic pathway that cleaves two-carbon acetyl-CoA units sequentially from the carboxyl end of fatty acyl-CoA molecules within the mitochondrial matrix:

Activation: Cytosolic fatty acids are converted to fatty acyl-CoA by fatty acyl-CoA synthetase (thiokinase) at the outer mitochondrial membrane, consuming 2 ATP equivalents (ATP → \to → AMP + P P i + PP_i + P P i ​ ).

The Carnitine Shuttle: Inner mitochondrial membranes are impermeable to CoA. Carnitine Palmitoyltransferase-1 (CPT-1) on the outer membrane replaces CoA with carnitine, forming acylcarnitine. Carnitine-acylcarnitine translocase (CACT) shuttles acylcarnitine into the matrix in exchange for free carnitine. CPT-2 on the inner membrane regenerates fatty acyl-CoA and free carnitine.

Rate-Limiting Control: CPT-1 is the rate-limiting enzyme of β \beta β -oxidation and is allosterically inhibited by malonyl-CoA , the initial intermediate of fatty acid synthesis. This prevents futile simultaneous synthesis and degradation of fatty acids.

The Four-Step β \beta β -Oxidation Spiral:

Oxidation: Acyl-CoA dehydrogenase generates a trans - Δ 2 \Delta^2 Δ 2 -enoyl-CoA and 1 F A D H 2 FADH_2 F A D H 2 ​ .

Hydration: Enoyl-CoA hydratase adds water, forming L-3-hydroxyacyl-CoA.

Oxidation: 3-Hydroxyacyl-CoA dehydrogenase forms 3-ketoacyl-CoA and 1 NADH .

Thiolysis: β \beta β -Ketothiolase cleaves the chain with CoASH, releasing 1 Acetyl-CoA and a fatty acyl-CoA shortened by two carbons.

2. Ketogenesis and Extrahepatic Utilization

Ketogenesis occurs exclusively within the mitochondrial matrix of hepatocytes when fatty acid β \beta β -oxidation generates acetyl-CoA at rates exceeding the capacity of the citric acid cycle:

Triggers: Prolonged fasting, starvation, poorly managed type 1 diabetes mellitus, and very-low-carbohydrate ketogenic diets. Under these conditions, hepatic gluconeogenesis depletes mitochondrial oxaloacetate, causing acetyl-CoA to accumulate.

Pathway: Two acetyl-CoA molecules condense to form acetoacetyl-CoA. Mitochondrial HMG-CoA Synthase (the rate-limiting enzyme of ketogenesis) condenses acetoacetyl-CoA with a third acetyl-CoA to form β \beta β -hydroxy- β \beta β -methylglutaryl-CoA (HMG-CoA) . HMG-CoA lyase then cleaves HMG-CoA into acetyl-CoA and acetoacetate .

Ketone Body Subtypes:

Acetoacetate: The primary metabolic ketone body.

β \beta β -Hydroxybutyrate: Formed by the reversible reduction of acetoacetate by mitochondrial β \beta β -hydroxybutyrate dehydrogenase utilizing NADH. It is the predominant ketone body circulating in blood.

Acetone: A volatile, non-metabolizable side product formed by spontaneous non-enzymatic decarboxylation of acetoacetate; excreted via expired air, imparting a characteristic fruity/sweet breath odor in diabetic ketoacidosis (DKA).

Extrahepatic Ketone Oxidation: Acetoacetate and β \beta β -hydroxybutyrate are transported to extrahepatic tissues (skeletal muscle, myocardium, renal cortex, and brain during starvation). Acetoacetate is reactivated to acetoacetyl-CoA by the enzyme succinyl-CoA:3-ketoacid CoA transferase (thiophorase) , transferring CoA from succinyl-CoA. The liver completely lacks thiophorase , ensuring that hepatocytes cannot utilize the ketone bodies they synthesize and must export them to peripheral tissues.

3. Fatty Acid Biosynthesis (De Novo Lipogenesis)

Occurs in the cytosol of hepatocytes, lactating mammary glands, and adipose tissue during energy surplus:

Citrate Shuttle: Mitochondrial acetyl-CoA condenses with oxaloacetate to form citrate, which crosses into the cytosol via the tricarboxylate transporter. Cytosolic ATP-citrate lyase cleaves citrate back into acetyl-CoA and oxaloacetate.

Rate-Limiting Step: Acetyl-CoA Carboxylase (ACC) carboxylates acetyl-CoA to form malonyl-CoA , consuming 1 ATP and requiring biotin ( B 7 B_7 B 7 ​ ). ACC is allosterically activated by citrate and dephosphorylated/activated by insulin; it is phosphorylated/inactivated by AMP-activated protein kinase (AMPK) and glucagon/epinephrine.

Fatty Acid Synthase (FAS): A multifunctional enzyme complex with an acyl carrier protein (ACP) containing 4'-phosphopantetheine (Vitamin B 5 B_5 B 5 ​ ). FAS sequentially condenses malonyl-CoA units, consuming NADPH (derived from the pentose phosphate pathway and malic enzyme), until releasing the 16-carbon saturated fatty acid palmitate (16:0) .

4. Cholesterol Biosynthesis

Occurs in the cytosol and endoplasmic reticulum of all nucleated cells, especially hepatocytes:

Three acetyl-CoA molecules form HMG-CoA via cytosolic HMG-CoA synthase.

HMG-CoA Reductase: Catalyzes the rate-limiting conversion of HMG-CoA to mevalonate , consuming 2 molecules of NADPH. HMG-CoA reductase is the primary pharmacological target of statins (competitive HMG-CoA reductase inhibitors like atorvastatin, rosuvastatin).

  • Cardiovascular Biomarkers and Clinical Lipid Profile Interpretation
  • Fasting Lipid Panel Reference Cutoffs

Standard lipid profiles assess Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG), with LDL-C calculated or directly measured.

Biomarker Desirable / Optimal Borderline High High / Elevated Very High Risk

Total Cholesterol < 200 mg/dL < 200\text{ mg/dL} < 200 mg/dL ( < 5.2 mmol/L < 5.2\text{ mmol/L} < 5.2 mmol/L ) 200 – 239 mg/dL 200–239\text{ mg/dL} 200–239 mg/dL ≥ 240 mg/dL \ge 240\text{ mg/dL} ≥ 240 mg/dL ( 6.2 mmol/L 6.2\text{ mmol/L} 6.2 mmol/L ) —

LDL Cholesterol < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ( < 2.6 mmol/L < 2.6\text{ mmol/L} < 2.6 mmol/L ); near optimal 100 – 129 mg/dL 100–129\text{ mg/dL} 100–129 mg/dL 130 – 159 mg/dL 130–159\text{ mg/dL} 130–159 mg/dL 160 – 189 mg/dL 160–189\text{ mg/dL} 160–189 mg/dL ≥ 190 mg/dL \ge 190\text{ mg/dL} ≥ 190 mg/dL

HDL Cholesterol ≥ 60 mg/dL \ge 60\text{ mg/dL} ≥ 60 mg/dL ( 1.55 mmol/L 1.55\text{ mmol/L} 1.55 mmol/L , protective) — Men: < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL ( 1.0 mmol/L 1.0\text{ mmol/L} 1.0 mmol/L , risk) Women: < 50 mg/dL < 50\text{ mg/dL} < 50 mg/dL ( 1.3 mmol/L 1.3\text{ mmol/L} 1.3 mmol/L , risk)

Triglycerides < 150 mg/dL < 150\text{ mg/dL} < 150 mg/dL ( < 1.7 mmol/L < 1.7\text{ mmol/L} < 1.7 mmol/L ) 150 – 199 mg/dL 150–199\text{ mg/dL} 150–199 mg/dL 200 – 499 mg/dL 200–499\text{ mg/dL} 200–499 mg/dL ≥ 500 mg/dL \ge 500\text{ mg/dL} ≥ 500 mg/dL ( 5.6 mmol/L 5.6\text{ mmol/L} 5.6 mmol/L , pancreatitis risk)

Non-HDL Cholesterol < 130 mg/dL < 130\text{ mg/dL} < 130 mg/dL ( < 3.4 mmol/L < 3.4\text{ mmol/L} < 3.4 mmol/L ) 130 – 159 mg/dL 130–159\text{ mg/dL} 130–159 mg/dL 160 – 189 mg/dL 160–189\text{ mg/dL} 160–189 mg/dL ≥ 190 mg/dL \ge 190\text{ mg/dL} ≥ 190 mg/dL

The Friedewald Formula and Clinical Limitations

In standard clinical laboratories, LDL-C is calculated rather than measured directly:

LDL-C (mg/dL) = Total Cholesterol − HDL-C − ( Triglycerides 5 ) \text{LDL-C (mg/dL)} = \text{Total Cholesterol} - \text{HDL-C} - \left( \frac{\text{Triglycerides}}{5} \right) LDL-C (mg/dL) = Total Cholesterol − HDL-C − ( 5 Triglycerides ​ ) LDL-C (mmol/L) = Total Cholesterol − HDL-C − ( Triglycerides 2.2 ) \text{LDL-C (mmol/L)} = \text{Total Cholesterol} - \text{HDL-C} - \left( \frac{\text{Triglycerides}}{2.2} \right) LDL-C (mmol/L) = Total Cholesterol − HDL-C − ( 2.2 Triglycerides ​ )

Where the term Triglycerides 5 \frac{\text{Triglycerides}}{5} 5 Triglycerides ​ estimates the cholesterol carried within VLDL particles (VLDL-C), assuming a constant 5 : 1 5:1 5 : 1 ratio of triglyceride to cholesterol mass in VLDL.

Caution

The Friedewald equation is invalid when:

Fasting serum triglycerides are ≥ 400 mg/dL \ge 400\text{ mg/dL} ≥ 400 mg/dL ( 4.5 mmol/L 4.5\text{ mmol/L} 4.5 mmol/L ) because the composition of triglyceride-rich particles becomes variable, leading to profound mathematical underestimation of LDL-C.

Chylomicrons are present (non-fasting samples or Type I/V hyperlipoproteinemia).

Dysbetalipoproteinemia (Type III hyperlipoproteinemia with elevated IDL/ β \beta β -VLDL).

Under these conditions, the laboratory must perform direct homogeneous enzymatic LDL-C measurement or the clinician must monitor Non-HDL Cholesterol .

Non-HDL Cholesterol and Atherogenic Dyslipidemia

Non-HDL Cholesterol ( TC − HDL-C \text{TC} - \text{HDL-C} TC − HDL-C ): Quantifies the cholesterol content of all circulating atherogenic apolipoprotein B-containing lipoproteins (LDL, VLDL, IDL, and Lp(a)). It does not require a fasting sample and remains reliable even when triglycerides exceed 400 mg/dL 400\text{ mg/dL} 400 mg/dL . In high-risk clinical guidelines, the non-HDL-C target is set at LDL-C goal + 30 mg/dL \text{LDL-C goal} + 30\text{ mg/dL} LDL-C goal + 30 mg/dL .

The Atherogenic Dyslipidemia Triad: Highly prevalent in metabolic syndrome, type 2 diabetes mellitus, and visceral obesity. Characterized by:

Elevated fasting triglycerides ( > 150 mg/dL > 150\text{ mg/dL} > 150 mg/dL ).

Low HDL-C ( < 40 mg/dL < 40\text{ mg/dL} < 40 mg/dL in men, < 50 mg/dL < 50\text{ mg/dL} < 50 mg/dL in women).

Predominance of Small, Dense LDL particles (Pattern B) . Small, dense LDL particles are prone to subendothelial arterial wall penetration, bind avidly to intimal proteoglycans, exhibit prolonged plasma half-life due to reduced LDL receptor affinity, and undergo rapid oxidation into cytotoxic oxidized LDL (oxLDL), initiating foam cell formation and atherosclerotic plaque progression.